Actively Recruiting
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Led by First Affiliated Hospital of Zhejiang University · Updated on 2024-12-31
36
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Philadelphia chromosome positive (Ph+) ALL is defined as ALL with translocation between chromosomes 9 and 22. And t(9;22)(q34;q11) is the most common chromosomal abnormality in ALL. Before the emergence of TKI, the prognosis of Ph+ ALL was extremely poor, and the long-term survival rate was only 10%-35%. Ph+ ALL accounts for about 30% of adult ALL. In this study, the investigators propose a treatment approach that combines Venetoclax with Olverembatinib and Predinisone in Ph+ B-ALL adults. The study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.
CONDITIONS
Official Title
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with new precursor B-cell acute lymphoblastic leukemia positive for Philadelphia chromosome
- Age 18 years or older
- ECOG performance status score between 0 and 2
- Expected survival time of at least 3 months
- No organ dysfunction limiting use of study treatment
- Able to understand the study and provide informed consent
- Men and women of childbearing age must agree to use effective contraception during treatment and for 12 months after last dose
You will not qualify if you...
- Accelerated phase or blast crisis of chronic myeloid leukemia
- Involvement of central nervous system or extramedullary lesions
- Previous systemic anti-leukemia treatment except allowed pretreatment
- History of myocardial infarction within 12 months or heart disease such as unstable angina, heart failure, uncontrolled hypertension, arrhythmia, or LVEF below 50%
- Severe lung, liver, or kidney disease limiting trial participation
- Other malignancies within last 5 years except localized thyroid or in situ skin cancer
- Elevated liver enzymes, bilirubin, or creatinine above specified limits
- Known HIV infection
- Conditions preventing use of study drugs
- Unable to understand or follow study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
J
Jie Jin, M.D.
CONTACT
C
Chenying Li, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here